Compounds > ro 24-0238
Page last updated: 2024-11-11

ro 24-0238

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ro 24-0238: PAF antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6439060
CHEMBL ID277245
SCHEMBL ID9120960
SCHEMBL ID9120974
MeSH IDM0197860

Synonyms (22)

Synonym
ro-24-0238
CHEMBL277245 ,
SCHEMBL9120960
SCHEMBL9120974
(2e,4e)-5-(4-methoxy-phenyl)-deca-2,4-dienoic acid ((r)-1-methyl-4-pyridin-3-yl-butyl)-amide
bdbm50011671
(2e,4e)-5-(4-methoxyphenyl)-n-[(2r)-5-pyridin-3-ylpentan-2-yl]deca-2,4-dienamide
2,4-decadienamide,5-(4-methoxyphenyl)-n-[(1r)-1-methyl-4-(3-pyridinyl)butyl]-, (2e,4e)-
5-(4-methoxyphenyl)-n-(1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide
(r-(e,e))-5-(4-methoxyphenyl)-n-(1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide
120555-31-9
2,4-decadienamide, 5-(4-methoxyphenyl)-n-(1-methyl-4-(3-pyridinyl)butyl)-, (r-(e,e))-
ro 24-0238
7g3ui0w9y5 ,
unii-7g3ui0w9y5
HY-19084
CS-6684
ro-24-238
ro-24-0238, (-)-
2,4-decadienamide, 5-(4-methoxyphenyl)-n-((1r)-1-methyl-4-(3-pyridinyl)butyl)-, (2e,4e)-
(2e,4e)-5-(4-methoxyphenyl)-n-((1r)-1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide
AKOS040742560
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet-activating factor receptorHomo sapiens (human)IC50 (µMol)0.04000.00030.63183.7000AID157738; AID59351
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID77001PAF-induced capillary permeability changes are studied in guinea pig skin test, after peroral administration of the compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID77730Ability to prevent PAF-induced bronchoconstriction in guinea pig when administered at a dose of 1 mg/kg intravenously1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID76658Ability to prevent PAF-induced bronchoconstriction in guinea pig when administered intravenously1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID76854Inhibition of PAF-induced bronchoconstriction in guinea pig after oral administration after two-hour pretreatment time1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID77727Ability to prevent PAF-induced bronchoconstriction in guinea pig 2 hr after administration (50 mg/kg perorally)1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID183139PAF-induced capillary permeability changes are studied in rat skin test, after intravenous administration of the compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID76267Inhibition of PAF-induced bronchoconstriction in the guinea pig, (1 mg/kg) intravenously at one-minute pretreatment time1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID76991Inhibitory activity against bronchoconstriction in guinea pig 2 hr after peroral administration of compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID183140PAF-induced capillary permeability changes are studied in rat skin test, after peroral administration of the compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID77728Ability to prevent PAF-induced bronchoconstriction in guinea pig 6 hr following 50 mg/kg p.o. administration.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID77002PAF-induced capillary permeability changes are studied in guinea pig test, after intravenous administration of the compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID59351PAF-antagonist activity determined in dog platelets by PAF-binding assay1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID157738Inhibition of [3H]PAF binding to dog platelets.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID76987Inhibition of PAF-induced bronchoconstriction in the guinea pig after intravenous administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID76269Inhibition of PAF-induced bronchoconstriction in the guinea pig after 1 mg/kg p.o. administration two hours prior to challenge.1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's6 (85.71)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.79 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		1.9710benzenes;
phenyl acetates
ro 24-4736
Ro 24-4736: structure given in first source; platelet activating factor antagonist		1.9710
web 2086
WEB 2086: structure given in first source; PAF antagonist		2.6730organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		1.97101,2,3-triazole
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.		4.28412-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
ConditionIndicatedRelationship StrengthStudiesTrials
Chronic Illness
[description not available]		03.3711
Palmoplantaris Pustulosis
[description not available]		03.3711
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		03.3711
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		08.3711
Eczema, Atopic
[description not available]		03.3811
Dermatitis, Atopic
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.		03.3811
Innate Inflammatory Response
[description not available]		01.9710
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		01.9710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		01.9710